Soretolide (Laboratoires Biocodex).

Abstract

Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials [299344]. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures [299344]. The company is currently discussing future development plans for this drug [410625].

• Authors: M O Fatope
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 6 Pg. 824-7 (Jun 2001) ISSN: 1472-4472 [Print] England
• PMID: 11572664 (Publication Type: Journal Article, Review)

Chemical References

• Anticonvulsants
• Isoxazoles
• soretolide

Topics

• Animals
• Anticonvulsants (adverse effects, pharmacokinetics, pharmacology, therapeutic use, toxicity)
• Contraindications
• Epilepsy (drug therapy)
• Humans
• Isoxazoles (adverse effects, pharmacokinetics, pharmacology, therapeutic use, toxicity)
• Structure-Activity Relationship